



HAL
open science

TREATMENT OF ACUTE LUNG INFLAMMATION BY PULMONARY DELIVERY OF ANTI-TNF-alpha SIRNA WITH PAMAM DENDRIMERS IN A MURINE MODEL

Adam Bohr, Nicolas Tsapis, Camilla Foged, Ilaria Andreana, Mingshi Yang,
Elias Fattal

► **To cite this version:**

Adam Bohr, Nicolas Tsapis, Camilla Foged, Ilaria Andreana, Mingshi Yang, et al.. TREATMENT OF ACUTE LUNG INFLAMMATION BY PULMONARY DELIVERY OF ANTI-TNF-alpha SIRNA WITH PAMAM DENDRIMERS IN A MURINE MODEL. *European Journal of Pharmaceutics and Biopharmaceutics*, 2020, 156, pp.114-120. 10.1016/j.ejpb.2020.08.009 . hal-02997033

HAL Id: hal-02997033

<https://hal.science/hal-02997033>

Submitted on 9 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**TREATMENT OF ACUTE LUNG INFLAMMATION BY PULMONARY DELIVERY OF
ANTI-TNF- α SIRNA WITH PAMAM DENDRIMERS IN A MURINE MODEL**

Adam Bohr^{1,2}, *Nicolas Tsapis*¹, *Camilla Foged*², *Ilaria Andreana*¹, *Mingshi Yang*², *Elias Fattal*¹

5

¹ Université Paris-Saclay, CNRS, Institut Galien Paris Sud, 92296, Châtenay-Malabry, France

² Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark

10 * Corresponding author:

Elias Fattal, Ph.D.; Châtenay-Malabry, France

Tel. : 0033146835568

E-mail : elias.fattal@u-psud.fr

15

Abstract

To improve the efficacy of nucleic acid-based therapeutics, *e.g.*, small interfering RNA (siRNA), transfection agents are needed for efficient delivery into cells. Several classes of dendrimers have been found useful as transfection agents for the delivery of siRNA because their surface can readily be functionalized, and the size of the dendriplexes they form with siRNA is within the range of conventional nanomedicine. In this study, commercially available generation 3 poly(amidoamine) (PAMAM) dendrimer was investigated for pulmonary delivery of siRNA directed against tumor necrosis factor (TNF) α for the treatment of acute lung inflammation. Delivery efficiency was assessed *in vitro* in the RAW264.7 macrophage cell line activated with lipopolysaccharide (LPS), and efficacy was evaluated *in vivo* in a murine model of LPS-induced lung inflammation upon pre-treatment with TNF- α siRNA. The PAMAM dendrimer-siRNA complexes (dendriplexes) displayed strong siRNA condensation and high cellular uptake in macrophages compared with non-complexed siRNA. Q-PCR analyses showed that the dendriplexes mediated efficient and specific TNF- α silencing *in vitro*, as compared to non-complexed siRNA and dendriplexes with negative control siRNA. Also *in vivo*, the PAMAM dendriplexes induced efficacious TNF- α siRNA inhibition, as compared to non-complexed siRNA, upon pulmonary administration to mice with LPS-induced lung inflammation. Hence, these data suggest that PAMAM dendrimers are promising for the local delivery of TNF- α siRNA in the treatment of lung inflammation via pulmonary administration.

35 Keywords

siRNA; TNF- α ; lung inflammation; dendriplex; macrophages, PAMAM dendrimer, lipopolysaccharide

1. Introduction

40 Oligonucleotide-based therapeutics, including siRNA, antisense oligonucleotides and miRNA, are applied to intervene with the expression of specific target genes and are thereby thought to mediate more specifically disease treatment than therapeutics based on small molecules or peptides/proteins. Inflammatory lung diseases are complex disorders that are usually treated with medications, which are relatively unspecific in their mode of action and are administered systemically, resulting in
45 increased drug exposure but also undesired side effects [1,2]. Here, local siRNA-based treatment may provide a much more specific and safe therapy in which certain inflammatory pathways can be targeted [3]. Of the many pro-inflammatory cytokines involved in lung inflammation processes, TNF- α is believed to play a central role in most inflammatory lung conditions, *e.g.*, chronic obstructive pulmonary disease (COPD), asthma, acute respiratory distress syndrome (ARDS) and acute lung
50 injury (ALI) [4]. More recently, it was shown to be a major target in the treatment of inflammatory flares in covid-19 infection-related ARDS [5]. Hence, TNF- α is a promising target for siRNA-based therapy against both acute and chronic lung inflammation.

A siRNA-based therapeutic targeting lung inflammation can be administered locally to the airways, either via inhalation or via nasal administration, where it can exert its effect directly in the inflamed
55 tissue. Local pulmonary delivery displays several therapeutic advantages, compared with systemic delivery, including (i) a quick onset of action, (ii) a reduced therapeutic dose required, and (iii) reduced side effects [6]. Besides, inhalation and nasal administration represent non-invasive routes of administration, which increases patient compliance, and the fast renal clearance of siRNA, observed after systemic administration, is reduced after local delivery [7].

60 Although numerous promising therapeutic targets and oligonucleotide sequences have been identified during the past years, which have resulted in a handful of recently marketed or in advanced clinical trial products, there are still significant challenges associated with their delivery [8,9]. Generally, siRNA displays poor chemical stability against nucleases and exhibits low cellular uptake and transfection [10]. Hence, it is pertinent to identify efficient delivery systems that can protect the

65 siRNA from degradation, facilitate its transport across the cell membrane and mediate endosomal
escape to achieve successful siRNA delivery to the cytosol [11,12]. Numerous transfection agents
have been identified for nucleic acid delivery, and they include, amongst others, cationic polymer-
and lipid-based nanocarriers, which are very efficient for cellular delivery, but they are often
associated with toxicity, even at relatively low doses [13,14].

70 Dendrimers are synthetic globular polymers displaying a high degree of surface functionality and
numerous possibilities for customizing their physicochemical properties, and they have shown great
potential for pharmaceutical applications, including the delivery of nucleic acid-based therapeutics
[15–17]. Cationic dendrimers like the commercially available polyamidoamine (PAMAM)
dendrimers have been shown to mediate efficient cellular uptake and transfection of siRNA *in vitro*
75 in multiple studies [18]. Although widely used *in vitro*, there are only a few studies that have tested
the ability of PAMAM dendrimers for siRNA transfection *in vivo* [19,20], and to date, no studies
have been performed evaluating pulmonary delivery of PAMAM dendrimers *in vivo*.

In this study, we investigated generation 3 PAMAM dendrimers as transfection agents for pulmonary
delivery of siRNA targeting TNF- α and examined their efficacy and safety in a murine acute lung
80 inflammation model. Generation 3 PAMAM dendrimers were selected because they display very
good efficiency for dendriplex formation. They were prepared at different dendrimer-siRNA ratios
and were characterized *in vitro* and *in vivo* concerning complexation, cellular uptake, cytotoxicity, *in*
vitro transfection efficiency and *in vivo* therapeutic efficacy at the RNA and protein levels,
respectively.

85

2. Materials and methods

2.1 Materials

2'-*O*-Methyl modified dicer substrate asymmetric siRNA duplex directed against TNF- α was
provided by Integrated DNA Technologies Inc. (IDT, Coralville, IA, USA) as dried, purified and
90 desalted powder. The duplex was re-annealed in a buffer consisting of 30 mM 4-(2-hydroxyethyl)-

piperazine-1-ethanesulfonic acid (HEPES) and 100 mM potassium acetate, pH 7.5. The TNF- α siRNA consisted of the following sequences:

TNF- α sense 5'-pGUCUCAGCCUCUUCUCAUUCCUGct-3', and

antisense 5'-AGCAGGAAUGAGAAGAGGCUGAGACAU-3',

95 where the underlined capital letters represent 2'-*O*-methylribonucleotides, lower-case letters represent deoxyribonucleotides and p represents a phosphate residue. A negative control siRNA sequence was purchased from Eurogentec (Eurogentec, Angers, France). The sequence of this negative control is not disclosed by the supplier. Fluorescently labeled siRNA with the dye TYE™ 665 was provided by IDT with a sequence targeting luciferase:

100 Sense 5'-pGGUUCCUGGAACAAUUGCUUUUAca-3',

Antisense 5'-UGUAAAAGCAAUUGUCCAGGAACCAG-3'

Primers for PCR were acquired from Eurofins MWG Operon (Ebersberg, Germany). PAMAM dendrimer (ethylenediamine core, generation 3.0) solution was acquired from Sigma-Aldrich (St Quentin Fallavier, France). RNase-free diethyl pyrocarbonate (DEPC)-treated water was used for all
105 solutions containing siRNA and dendrimers. All experiments with siRNA and dendrimers were performed at 25 °C in 10 mM HEPES buffer (pH 7.4) unless otherwise stated. Lipopolysaccharide (LPS) (γ -irradiated, <1% protein) was obtained from Sigma-Aldrich (St Quentin Fallavier, France). All additional chemicals used were obtained commercially and were of analytical grade.

2.2 Preparation of dendriplexes

110 Dendriplexes were prepared in 10 mM HEPES buffer at a nitrogen-to-phosphate (N/P) ratio of 5, 10, 20 and 40, respectively. Dendrimer solutions of 20 μ l were added to a siRNA solution of 80 μ l and subsequently vortexed, resulting in a 5 μ M final siRNA concentration and 37, 75, 150 and 300 μ M final dendrimer concentration at N/P ratios 5, 10, 20 and 40, respectively. The mixtures were left for 10 min at room temperature to allow complex the formation. A siRNA concentration of 500 nM was
115 used for dynamic light scattering measurements, and a siRNA concentration of 5 μ M was used for gel electrophoresis studies. Amicon Ultra-0.5mL centrifuge tubes (Thermo-Fisher, Villebon, France)

were used for upconcentrating the dendriplex suspensions by centrifugation of the samples at 13,000 g for 20 min.

2.3 Characterization of dendriplexes

120 The particle size distribution and polydispersity index (PDI) of the dendriplexes were determined by dynamic light scattering using the photon correlation spectroscopy technique, and their zeta potential was estimated by using laser-Doppler micro-electrophoresis using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK) equipped with a 633 nm laser and 173° detection optics. The complexation of dendrimers and siRNA into dendriplexes was assessed using gel electrophoresis. 125 Electrophoresis was carried out applying 1% (w/v) agarose gels (Promega, city, USA) containing 5 μ L 2.5 mg/mL ethidium bromide solution, and samples consisting of 0.1 nmol siRNA were loaded into each well of the gels. The gels were run for 20 min at 100 V in Tris-borate-EDTA (TBE) buffer (pH 8.2). Visualization of the siRNA bands was performed using an MF-ChemiBIS gel imaging system (DNR Bio-Imaging Systems, Neve Yanim, Israel).

130 2.4 Cell culture

A murine macrophage cell line RAW264.7 was purchased from the American Type Culture Collection (ATCC, Molsheim, France) and cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) (Aldrich, St Quentin Fallavier, France) supplemented with 10% (v/v) fetal bovine serum (PAA Laboratories, Pasching, Austria) and 100 U/ml penicillin, 100 μ g/ml streptomycin. Cells 135 were grown under a controlled atmosphere with 5% CO₂/95% O₂ at 37°C and were sub-cultured twice per week by washing and gently scraping the cells from the culture flask. Cells were used between passages 5 and 12.

2.5 Cell viability

The cellular viability of the RAW264.7 cells was assessed by using the 3-(4,5-Dimethylthiazol-2- 140 Yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay. Cells were prepared in suspension, counted and seeded in 96-well plates at a density of 8×10^3 cells per well and left to attach overnight. The cells

were subsequently incubated with dendriplexes (N/P ratio 5) at different concentrations for a period of 24 h. To each well with 100 μ l culture medium, 10 μ l of MTT-solution (5 mg/ml in PBS, pH 7.4) was added and the plate was incubated for 2 h at 37 °C. Subsequently, the medium was replaced with
145 200 μ l dimethylsulfoxide, and the absorbance was measured at 570 nm, using a microplate reader (FLUOstar OPTIMA, BMG labtech, Germany).

2.6 Cellular uptake

Cellular uptake of siRNA was assessed in RAW264.7 cells using fluorescence microscopy and flow cytometry, respectively. For fluorescence microscopy, the cells were seeded in chambered cover
150 slides μ -Slide 8 well (Ibidi, Planegg, Germany) at a density of 5×10^4 cells per well and cultured for 12h. The cells were then treated with fluorescently labeled siRNA for 4 h (at an N/P ratio of 5 for dendriplexes and a concentration of 100 nM siRNA), washed with PBS and fixed using 4% (v/v) paraformaldehyde. Microscopy was performed using a Zeiss LSM 510 (Carl Zeiss, Jena, DE) fluorescence microscope equipped with a 1 mW helium-neon laser and a plan-apochromat 63X
155 objective lens (numerical aperture 1.40, oil immersion). Images were captured at a 63X magnification and overlaid with differential interferential contrast (DIC) images. For flow cytometry, the cells were cultured in 12-well plates at a density of 5×10^4 cells per well. The cells were treated with fluorescently labeled siRNA for 4 h (at an N/P ratio of 5 for dendriplexes and a concentration of 100
160 nM siRNA) and subsequently resuspended and analyzed using an Accuri C6 (BD biosciences, Franklin Lakes, NJ, USA) flow cytometer. The mean fluorescence intensity (MFI) was used to determine the relative cell uptake (the ratio between treated and non-treated samples), expressed in arbitrary units.

2.7 Cell transfection

Cell transfection studies were performed as described previously [17][21]. Briefly, RAW264.7 cells
165 were seeded at a density of 1×10^6 cells per well in 6-well culture plates. Dendriplexes prepared at an N/P ratio of 5 were transferred to culture plates to achieve a final siRNA concentration of 100 nM,

and they were incubated for 24 h. Three hours before collection, the cells were exposed to lipopolysaccharide (LPS) dispersed in PBS to obtain an LPS concentration of 5 ng/ml. Negative controls were only given PBS, and positive controls only received LPS, but were not treated with
170 siRNA. For collection, the culture medium was removed from the wells, 1 ml ice-cold TRIzol (Thermo Fisher, Villebon-sur-Yvette, France) was added to each well, and the cells were scraped and homogenized by pipetting.

RNA extraction was performed following the stepwise instructions provided with the TRIzol reagent, and the total RNA content of the extracts was assessed using a Biomate 3 UV spectrophotometer
175 (Thermo Fisher) with a TrayCell ultra-micro cell (Hellma Analytics, Paris, France). Additional quality control of the extracts was performed with an RNA LabChip, using an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). Reverse transcription was performed for 1 µg RNA extracts using a mix of primers [17] and an iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA). The cDNA was diluted 1:10 (v:v) in PCR-grade water and stored at -80°C
180 until further use. TNF-α mRNA silencing was assessed by real-time reverse transcription-polymerase chain reaction (RT-PCR), essentially as previously described [21]. Real-time PCR was performed using a C1000 Thermal Cycler instrument with a CFX96 Real-Time System (Biorad) with the following cycling conditions: Initial denaturation step at 95 °C for 5 min, followed by 35 cycles including (i) denaturation at 95 °C for 10 s, (ii) annealing at 60 °C for 10 s, and (iii) elongation at 72
185 °C for 10 s. The CFX manager software 3.0 (Biorad) was used for crossing point (CP) analysis, and the values were normalized against the average of the two reference genes ribosomal protein, large P2 (RPLP2) and glucoronidase b (GUSb). The reference genes were selected based on a screening study of eight reference candidates [17].

2.8 In vivo studies

190 All animal experiments were conducted following the European rules (86/609/EEC and 2010/63/EU) and the Principles of Laboratory Animal Care and the national French legislation (Decree No. 2013-118 of February 1, 2013). All experimental procedures were refined to provide for maximal comfort


and minimal stress to the animals. Female Swiss CD-1 outbred mice were purchased from Envigo (Gannat, France), and all experiments were performed using mice at the age of 6 to 8 weeks. The mice were housed in groups of four with access to water and food *ad libitum* and kept at a constant temperature (19-22°C) and relative humidity (45-65%).

2.8.1 Acute lung inflammation model

A well-known procedure for LPS-induced lung inflammation [22–24] was modified using Swiss CD-1 mice. The mice were anesthetized by intraperitoneal (i.p.) injection of 200 µl Ketamine (3.5 mg/ml)/Xylazine solution (5 mg/ml). Subsequently, LPS solution (3.2 mg/kg) was administered to the mice *via* intranasal administration (1.2 µl LPS solution / g of mouse weight). For extraction of the bronchoalveolar lavage (BAL), the mice were euthanized *via* an overdose of pentobarbital (i.p. injection of 200 µl 20 mg/ml pentobarbital solution). Subsequently, the trachea was cannulated with a catheter, and the lungs were flushed twice with 0.3 ml PBS. The BAL was centrifuged at 400 g for 10 min, the supernatant was stored at -20 °C for protein quantification and TNF- α determination.

2.8.2 Prophylactic siRNA treatment

Mice were dosed with siRNA as a prophylactic treatment before inducing lung inflammation (Figure 1). Non-complexed siRNA and dendriplexes (N/P ratio of 5) were administered *via* intranasal administration similar to LPS administration at a siRNA concentration of 1.0 mg/kg using an average volume of 30 µl siRNA solution 24 h before LPS challenge. The BAL was extracted 4 and 72 h, respectively, after the LPS challenge, and a minimum of five mice was included in each sample group. Negative controls were dosed twice with PBS, and positive control mice were first dosed with PBS and subsequently treated with LPS.



215 Figure 1. Schematic illustration of the *in vivo* experimental procedure. Mice were prophylactically administered with treatments 24h before inflammation induction by LPS. BAL was collected either at 4 or 72h for TNF- α determination.

2.8.3 TNF- α measurements

The TNF- α protein levels were assessed by using the Cytometric Bead Array - Mouse inflammation
 220 kit (BD biosciences). The supernatants of BAL samples were diluted in assay diluent from the kit, and the samples were prepared following the manufacturer's instructions. The BAL TNF- α levels were quantified using an Accuri C6 flow cytometer, where 2000 ROI counts were measured for each sample. All samples were prepared in duplicates and analyzed using the BD Accuri C6 software.

2.9 Statistics

225 The data of the *in vitro* studies are reported as mean values \pm SD, and the data for the *in vivo* studies are reported as mean values \pm SEM. The statistical significance was determined using either a two-tailed, unpaired Student's t-test or ANOVA, with the statistical significance set at * $p < 0.05$, ** $p < 0.01$.

3.1 Dendriplex formation

All dendriplexes displayed an average size between 127-153 nm and a PDI between 0.19-0.27 (Table 1). There was no clear correlation between the N/P ratio of the dendriplexes and their resulting sizes and PDIs although it has previously been shown that the sizes of PAMAM dendriplexes decrease with an increase in N/P ratio [25]. Positive zeta potential values were observed for all N/P ratios, indicating a net positive surface charge and condensation of siRNA. The zeta potential increased significantly ($p < 0.05$, ANOVA) as a function of the N/P ratio, which can be attributed to the increase in charge ratio, and it also indicates improved siRNA condensation at higher N/P ratios.

240 Table 1. Z-average, polydispersity index (PDI) and zeta potential of dendriplexes prepared in HEPES buffer (10 mM, pH 7.4). Data points represent mean values \pm SD ($n \geq 3$). Zeta potential values were significantly different from each other (ANOVA, $p < 0.05$)

N/P ratio	Z-average (nm)	PDI	Zeta potential (mV)
5	152 \pm 6	0.22 \pm 0.04	36 \pm 2
10	141 \pm 4	0.19 \pm 0.02	39 \pm 1
20	127 \pm 7	0.27 \pm 0.03	45 \pm 4
40	153 \pm 11	0.24 \pm 0.03	46 \pm 4

Gel electrophoresis studies using EtBr to stain the siRNA were performed to assess qualitatively the binding between siRNA and dendrimer at different N/P ratios. These studies show binding between siRNA and dendrimers at all N/P ratios (Figure 2). In all cases, the major part of the siRNA was retained inside the dendriplexes in the presence of EtBr, as compared to free, non-complexed siRNA. Based on the size and binding results of the dendriplexes, subsequent experiments were performed at an N/P ratio of 5 as a compromise between the complexation and high siRNA loading as shown by gel retardation assay. Moreover, this ratio was selected to reduce the cytotoxicity as much as possible.





Figure 2. Agarose gel electrophoresis of dendriplexes (0.9 μ g siRNA per lane). A: Non-complexed siRNA; B-E: dendriplexes prepared at N/P ratios of 5, 10, 20 and 40, respectively.

255

3.2 Cell viability and uptake

Cell viability studies using the MTT assay showed that the dendriplexes were well tolerated up to a siRNA concentration of 800 nM (N/P ratio 5) (Figure 3A). A similar profile was observed for non-complexed dendrimers (not shown). The cytotoxicity measured for the dendriplexes is relatively low, as compared to other cationic transfection agents, *e.g.*, polyethyleneimine (PEI) and poly-l-lysine [26], which indicates that PAMAM dendriplexes are well tolerated by RAW264.7 cells. Cellular uptake assessed at a subtoxic concentration of 100 nM siRNA using flow cytometry showed that the uptake of non-complexed siRNA was low and did not increase over time (Figure 3B). In contrast, the cellular uptake of the dendriplexes increased gradually with time, resulting in a six-fold higher uptake after 4 h, as compared to non-complexed siRNA. Confocal fluorescence microscopy images captured after 4 h incubation showed no visible fluorescence inside the cells incubated with non-complexed siRNA, which also suggests a very low uptake of siRNA (Figure 4). Cells incubated with dendriplexes showed substantial fluorescence inside the cells with numerous red dots distributed within every cell (Figure 4). The confocal fluorescence microscopy images indicate efficient dendrimer-mediated cellular uptake of siRNA, which support the flow cytometry results.

270



275 Figure 3. Cell viability of RAW 264.7 cells as a function of siRNA concentration, measured after 24 h
 incubation with dendriplexes (A). Cellular uptake of siRNA (100 nM) in RAW 264.7 cells as a function of
 incubation time, measured as siRNA mean fluorescence intensity (MFI) using flow cytometry (B). Data
 points represent mean values \pm SD ($n \geq 3$). For non-complexed siRNA, the error bars are smaller than the
 280 points.




Figure 4. Representative images of the cellular uptake of dendriplexes (100 nM siRNA) in RAW
 264.7 cells after 4 h incubation. Overlay of a bright field and fluorescence image for untreated cells
 (A) and cells incubated with non-complexed siRNA (B) and dendriplexes (C).

285 3.3 TNF- α silencing in cells

Transfection using TNF- α siRNA and negative control siRNA in macrophages activated with LPS
 was evaluated at the mRNA level using qPCR (Figure 5). An siRNA containing 2'-O-methylated
 nucleotides in the antisense strand was selected to minimize the innate immune response that occurs
 with the administration of siRNA. Another reason is provided by the greater stability of this
 290 chemically modified siRNA. Non-complexed TNF- α siRNA mediated little but statistically
 significant inhibition (26%) of the TNF- α mRNA expression ($p < 0.05$), as compared with the
 negative control siRNA, and 28% inhibition, as compared to the LPS-challenged positive control (p
 < 0.05). In contrast, the PAMAM dendriplexes with TNF- α siRNA mediated 86% inhibition of TNF-

α expression, as compared to the LPS-challenged positive control ($p < 0.001$) and 58% inhibition
295 compared with the PAMAM dendriplexes with negative control siRNA ($p < 0.01$), which represents
a substantially greater inhibition compared with non-complexed siRNA. Hence, PAMAM
dendriplexes display high potential for TNF-α silencing, but some unspecific silencing of PAMAM
dendriplexes with negative control siRNA was also observed. The transfection data support the
observations from the cell uptake studies, indicating the improved performance of dendriplexes, as
300 compared with non-complexed siRNA.




Figure 5. TNF-α mRNA silencing in RAW 264.7 cells by dendriplexes. Samples were normalized
to the LPS-treated cells (Control +) without siRNA, and the results denote the TNF-α mRNA
expression level of cells treated with TNF-α siRNA, relative to transfection with negative control
siRNA. The samples correspond to a siRNA concentration of 50 nM and an N/P ratio of 5. Results
305 denote mean values \pm SD ($n \geq 3$). Statistical significance: * $p < 0.05$, ** $p < 0.01$.

3.4 *In vivo* silencing and modulation of inflammation

To induce gene silencing in the lungs, siRNA was delivered using PAMAM dendrimers. Many
310 studies have examined the effect of PAMAM dendrimers on lungs. At first, it was shown that 83%
of the PAMAM dendrimer dose remain in the lungs 6.5 h post pulmonary administration to mice?
(Mol Pharm. 2016 Jun 6; 13(6): 1866–1878). Several studies have stressed the lung biocompatibility
of PAMAM dendrimers and the absence of any inflammatory response in the lungs (Dong et al. J
Pharm Sci 2011 May;100(5):1866-78 Environ Sci Pollut Res Int. 2016 Feb;23(3):2128-37).

315 In several studies, it has been shown that intranasal challenge with LPS results in lung inflammation characterized by an increase in the levels of TNF- α as well as other pro-inflammatory cytokines in the lungs [27]. Besides, the massive recruitment of macrophages and neutrophils takes place rapidly, and the inflammatory process lasts for several days [28,29]. Chronic inflammation is usually characterized by occasional flare-ups, including COPD, asthma, and cystic fibrosis, which represent
320 the most common reason for contact between the patient and the health care system [30]. These flare-ups can be triggered by both external and internal stimuli, *e.g.*, exposure to pollutants and increased stress levels. Hence, the optimal treatment strategy may be a prophylactic measure taken to reduce the response to such stimuli. Therefore, in this study, we investigated the therapeutic effect of a prophylactic treatment with siRNA given 24 h before inducing an inflammatory response with LPS.

325 TNF- α levels were compared for mice treated with LPS (Control +) as well as untreated mice (Control -) and were evaluated to assess the potential inflammatory response of the non-complexed siRNA and the dendriplexes. Dendriplexes were administered at a siRNA dose of 1 mg/kg, based on previous siRNA studies on pulmonary delivery, where doses ranging between 0.6-3 mg/kg were administered [31–33].

330 The TNF- α concentrations in the BAL were measured 4 h and 72 h after exposing the mice to LPS. The TNF- α levels measured after 4 h (Figure 6A) indicated a significant ($p < 0.05$) reduction in TNF- α for subjects treated with dendriplex TNF- α siRNA as compared to negative control or to free TNF- α siRNA, whereas mice treated with non-complexed TNF- α siRNA did not show any significant difference from Control +. Mice treated with dendriplex TNF- α siRNA demonstrated 24% TNF- α
335 silencing compared with those treated with LPS-treated positive control and a 24% TNF- α silencing compared with the dendriplex negative control siRNA. Mice treated with non-complexed TNF- α siRNA showed a mere and non-significant 2% TNF- α silencing compared with the LPS-treated control and a 7% TNF- α silencing compared with the non-complexed control siRNA. This indicates the need for a transfection agent for the delivery of siRNA to the lungs and that dendriplexes mediate
340 a substantial inhibition of TNF- α expression in the early stage of LPS-induced lung inflammation. The TNF- α levels measured 72 h after challenging the mice with LPS (Figure 6B) were significantly

($p < 0.05$) reduced for the two groups treated with TNF- α siRNA, as compared to the corresponding groups treated with negative control siRNA. Mice treated with non-complexed TNF- α siRNA demonstrated significant ($p < 0.05$) TNF- α silencing of 34% compared with the LPS-treated positive control, and a significant TNF- α silencing of 23% ($p < 0.05$) compared with the non-complexed negative control siRNA. In comparison, the dendriplex TNF- α siRNA resulted in a significant TNF- α silencing of 21% ($p < 0.05$) compared with the dendriplex negative control siRNA and a TNF- α silencing of 14% compared with the LPS-treated positive control. This indicates that non-complexed siRNA resulted in slightly more sustained inhibition of TNF- α expression than the dendriplex TNF- α siRNA comparing the expression at 4 h and 72 h after the LPS challenge.




Figure 6. TNF- α concentration in BAL of mice challenged with LPS 24 h after administration of siRNA treatment and euthanized 4 h (A) and 72 h (B) after the LPS challenge, followed by extraction of BAL. Control - and Control + denote untreated and LPS-treated mice, respectively. Data points represent mean values \pm SEM. $n \geq 5$. Statistical significance: * $p < 0.05$.

Several polymeric carriers have been investigated for siRNA delivery and many systems have demonstrated successful gene silencing and therapeutic efficacy, including dendrimers. In this study, PAMAM dendrimer was studied as a transfection agent for siRNA delivery to the lungs and assessed in an acute lung inflammation model in mice. The study showed that the dendriplexes provided an

efficient delivery *in vitro* with high transfection performance and cellular uptake in RAW264.7
macrophages. Yet, based on *in vivo* studies it was demonstrated that dendriplexes with TNF- α siRNA
365 resulted in improved performance compared with non-complexed TNF- α siRNA at early time e.g 4
h after LPS challenge and lower performance compared with non-complexed TNF- α siRNA 72h after
LPS challenge, meaning that more frequent administrations are needed in patients displaying strong
lung inflammation.

In this study, TNF- α was selected as a target because this proinflammatory cytokine plays a central
370 role in lung diseases and its actions are numerous and quite diverse being linked to many lung diseases
including asthma, COPD, ALI/ARDS, sarcoidosis, and interstitial pulmonary fibrosis [34]. The data
show that a quick response occurs not lasting long which might be related to a very quick dissociation
in the lungs. Thanki et al. [7] demonstrated that although part of complexed siRNA was staying in
the lungs, around 50% was permeating across the air-blood barrier within 6 h and subsequently
375 excreted via the kidneys [7]. The low stability as well might explain why the efficacy does not stand
for longer times. In a previous work [17,35] involving phosphated dendrimers, we compared two
dendrimers in a lung injury model using the same anti-TNF- α siRNA. It was clear from these studies
that dendriplexes with the lowest Kd were the more active with a long-lasting inhibition effect not
only on TNF- α but other cytokines as well. This could be achieved with more frequent lung
380 administration but would also raise the question of chronic toxicity which needs to be further
evaluated. Applying higher-generation PAMAM dendrimers would have increased stability and
efficacy but again could have induced much higher toxicity. Finally, two factors might explain the
lower efficacy of dendriplexes at 72 hours. The first is the high stability of methylated siRNA and the
second is the fast elimination of dendriplexes due to the mucociliary clearance, as compared to the
385 clearance of non-complexed molecules that can penetrate in the deep lungs without undergoing this
elimination process.

5. Conclusion

In the current study, the performance of PAMAM dendrimers was investigated as a delivery system

for siRNA transfection, specifically for the local treatment of lung inflammation. We demonstrate a
390 good ability to condensate siRNA, high cellular internalization rate and a specific and efficient gene
silencing of TNF- α *in vitro* in macrophages for PAMAM-based dendriplexes with TNF- α targeting
siRNA. *In vivo* studies in a murine acute lung inflammation model showed silencing of TNF- α for
the dendriplexes although less pronounced compared to *in vitro* performance. The findings suggest
that TNF- α targeting siRNA can be used as a local treatment for overall suppression of lung
395 inflammation and can be used as a prophylactic treatment administered one day before an
inflammatory trigger.

Acknowledgments

The authors would like to thank the Danish Council for Independent Research (Grant No. DFF-12-
131927) for financial support of this project. Further, Valérie Nicolas and Claudine Delomenie are
400 acknowledged for their help with confocal microscopy and qPCR respectively. The authors would
like to thank N. Szely, J. Vergnaud and A. Biola-Vidamment for fruitful discussion. This study has
been carried out with financial support from the Commission of the European Communities, Priority
3 “Nanotechnologies and Nanosciences, Knowledge-Based Multifunctional Materials, New
Production Processes, and Devices” of the Sixth Framework Programme for Research and
405 Technological Development (Targeted Delivery of Nanomedicine: NMP4-CT-2006-026668). The
authors would also like to acknowledge the financial support provided by COST-European Cooperation in
Science and Technology, to the COST Action MP1404: Simulation and pharmaceutical technologies for
advanced patient-tailored inhaled medicines (SimInhale).

References

- 410 [1] Y. Mushtaq, The COPD pipeline, *Nat. Rev. Drug Discov.* 13 (2014) 253–254.
- [2] D. Singh, A. Agusti, A. Anzueto, P.J. Barnes, J. Bourbeau, B.R. Celli, G.J. Criner, P. Frith,
D.M.G. Halpin, M. Han, M.V. López Varela, F. Martinez, M. Montes de Oca, A. Papi, I.D.
Pavord, N. Roche, D.D. Sin, R. Stockley, J. Vestbo, J.A. Wedzicha, C. Vogelmeier, Global
Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung

- 415 Disease: the GOLD science committee report 2019, *Eur. Respir. J.* 53 (2019) 1900164.
doi:10.1183/13993003.00164-2019.
- [3] G. Caramori, I.M. Adcock, A. Di Stefano, K.F. Chung, Cytokine inhibition in the treatment of COPD, *Int J Chron Obs. Pulmon Dis.* 9 (2014) 397–412.
- [4] S. Mukhopadhyay, J.R. Hoidal, T.K. Mukherjee, Role of TNF α in pulmonary
420 pathophysiology, *Respir. Res.* 7 (2006) 1–9. doi:10.1186/1465-9921-7-125.
- [5] M. Feldmann, R.N. Maini, J.N. Woody, S.T. Holgate, G. Winter, M. Rowland, D. Richards, T. Hussell, Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed, *Lancet.* 6736 (2020) 10–13. doi:10.1016/S0140-6736(20)30858-8.
- [6] O.M. Merkel, I. Rubinstein, T. Kissel, siRNA Delivery to the lung: What’s new?, *Adv. Drug
425 Deliv. Rev.* 75 (2014) 112–128. doi:10.1016/j.addr.2014.05.018.
- [7] K. Thanki, D. van Eetvelde, A. Geyer, J. Fraire, R. Hendrix, H. Van Eygen, E. Putteman, H. Sami, C. de Souza Carvalho-Wodarz, H. Franzyk, H.M. Nielsen, K. Braeckmans, C.M. Lehr, M. Ogris, C. Foged, Mechanistic profiling of the release kinetics of siRNA from lipidoid-polymer hybrid nanoparticles in vitro and in vivo after pulmonary administration, *J. Control.
430 Release.* (2019). doi:10.1016/j.jconrel.2019.08.004.
- [8] N. Shajari, B. Mansoori, S. Davudian, A. Mohammadi, B. Baradaran, Overcoming the challenges of siRNA delivery: nanoparticle strategies, *Curr. Drug Deliv.* 14 (2017) 36–46.
- [9] R.M. Schiffelers, E.O. Blenke, E. Mastrobattista, Oligonucleotides, in: *Pharm. Biotechnol.*, Springer, 2019: pp. 305–322.
- 435 [10] T.L. Nascimento, H. Hillaireau, E. Fattal, Nanoscale particles for lung delivery of siRNA, *J. Drug Deliv. Sci. Technol.* (2012). doi:10.1016/S1773-2247(12)50010-9.
- [11] K.A. Whitehead, R. Langer, D.G. Anderson, Knocking down barriers: advances in siRNA delivery, *Nat. Rev. Drug Discov.* 8 (2009) 129.
- [12] S.C. Semple, A. Akinc, J. Chen, A.P. Sandhu, B.L. Mui, C.K. Cho, D.W.Y. Sah, D.
440 Stebbing, E.J. Crosley, E. Yaworski, Rational design of cationic lipids for siRNA delivery, *Nat. Biotechnol.* 28 (2010) 172–176.

- [13] L. Jin, X. Zeng, M. Liu, Y. Deng, N. He, Current progress in gene delivery technology based on chemical methods and nano-carriers, *Theranostics*. 4 (2014) 240–255.
- [14] K. Gao, L. Huang, Non-viral methods for siRNA delivery, *Mol. Pharm.* 6 (2009) 651.
- 445 [15] A.-M. Caminade, D. Yan, D.K. Smith, Dendrimers and hyperbranched polymers, *Chem. Soc. Rev.* 44 (2015) 3870–3873.
- [16] A.-M. Caminade, J.-P. Majoral, Nanomaterials based on phosphorus dendrimers, *Acc. Chem. Res.* 37 (2004) 341–348.
- [17] A. Bohr, N. Tsapis, I. Andreana, A. Chamarat, C. Foged, C. Delomenie, M. Noiray, N. El
450 Brahmi, J.P. Majoral, S. Mignani, E. Fattal, Anti-Inflammatory Effect of Anti-TNF- α SiRNA
Cationic Phosphorus Dendrimer Nanocomplexes Administered Intranasally in a Murine
Acute Lung Injury Model, *Biomacromolecules*. 18 (2017) 2379–2388.
doi:10.1021/acs.biomac.7b00572.
- [18] S. Biswas, V. Torchilin, Dendrimers for siRNA delivery, *Pharmaceuticals*. 6 (2013) 161–
455 183.
- [19] V. Leiro, S. Duque Santos, A. Paula Pego, Delivering siRNA with Dendrimers: In Vivo
Applications, *Curr. Gene Ther.* 17 (2017) 105–119.
- [20] J. Li, H. Liang, J. Liu, Z. Wang, Poly (amidoamine)(PAMAM) dendrimer mediated delivery
of drug and pDNA/siRNA for cancer therapy, *Int. J. Pharm.* 546 (2018) 215–225.
- 460 [21] L.B. Jensen, J. Griger, B. Naeye, A.K. Varkouhi, K. Raemdonck, R. Schiffelers, T.
Lammers, G. Storm, S.C. de Smedt, B.S. Sproat, H.M. Nielsen, C. Foged, Comparison of
Polymeric siRNA Nanocarriers in a Murine LPS-Activated Macrophage Cell Line: Gene
Silencing, Toxicity and Off-Target Gene Expression, *Pharm. Res.* 29 (2012) 669–682.
doi:10.1007/s11095-011-0589-0.
- 465 [22] S. Ferretti, O. Bonneau, G.R. Dubois, C.E. Jones, A. Trifilieff, IL-17, produced by
lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway
neutrophilia: IL-15 as a possible trigger, *J. Immunol.* 170 (2003) 2106–2112.
- [23] I. a J. Giebelen, D.J. van Westerloo, G.J. LaRosa, A.F. de Vos, T. van der Poll, Local

- stimulation of alpha7 cholinergic receptors inhibits LPS-induced TNF-alpha release in the
470 mouse lung., *Shock*. 28 (2007) 700–3. doi:10.1097/shk.0b013e318054dd89.
- [24] S. Knapp, S. Florquin, D.T. Golenbock, T. Van Der Poll, the LPS-Induced Lung
Inflammation In Vivo 1, *J. Immunol.* 176 (2006) 3189–3195.
doi:10.4049/jimmunol.176.5.3189.
- [25] L.B. Jensen, G.M. Pavan, M.R. Kasimova, S. Rutherford, A. Danani, H.M. Nielsen, C.
475 Foged, Elucidating the molecular mechanism of PAMAM-siRNA dendriplex self-assembly:
Effect of dendrimer charge density, *Int. J. Pharm.* 416 (2011) 410–418.
doi:10.1016/j.ijpharm.2011.03.015.
- [26] Y. Wang, W. Kong, Y. Song, Y. Duan, L. Wang, G. Steinhoff, D. Kong, Y. Yu,
Polyamidoamine dendrimers with a modified pentaerythritol core having high efficiency and
480 low cytotoxicity as gene carriers, *Biomacromolecules*. 10 (2009) 617–622.
- [27] J. Dhariwal, J. Kitson, R.E. Jones, G. Nicholson, T. Tunstall, R.P. Walton, G. Francombe, J.
Gilbert, A.J. Tan, R. Murdoch, O.M. Kon, P.J. Openshaw, T.T. Hansel, Nasal
lipopolysaccharide challenge and cytokine measurement reflects innate mucosal immune
responsiveness, *PLoS One*. 10 (2015). doi:10.1371/journal.pone.0135363.
- 485 [28] M.E. Poynter, C.G. Irvin, Y.M.W. Janssen-Heininger, A prominent role for airway epithelial
NF-κB activation in lipopolysaccharide-induced airway inflammation, *J. Immunol.* 170
(2003) 6257–6265.
- [29] J.M. Litell, M.N. Gong, D. Talmor, O. Gajic, Acute Lung Injury: Prevention May Be the
Best Medicine, *Respir. Care*. 56 (2011) 1546–1554. doi:10.4187/respcare.01361.
- 490 [30] P. Hernandez, M. Balter, J. Bourbeau, R. Hodder, Living with chronic obstructive pulmonary
disease: a survey of patients' knowledge and attitudes, *Respir. Med.* 103 (2009) 1004–1012.
- [31] J. Conde, F. Tian, Y. Hernandez, C. Bao, D. Cui, K.-P. Janssen, M.R. Ibarra, P. V Baptista,
T. Stoeger, J.M. de la Fuente, In vivo tumor targeting via nanoparticle-mediated therapeutic
siRNA coupled to inflammatory response in lung cancer mouse models., *Biomaterials*. 34
495 (2013) 7744–7753. doi:10.1016/j.biomaterials.2013.06.041.

- [32] J.E. Dahlman, C. Barnes, O.F. Khan, A. Thiriot, S. Jhunjunwala, T.E. Shaw, Y. Xing, H.B. Sager, G. Sahay, L. Speciner, In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight, *Nat. Nanotechnol.* 9 (2014) 648–655.
- 500 [33] K. Kusumoto, H. Akita, T. Ishitsuka, Y. Matsumoto, T. Nomoto, R. Furukawa, A. El-Sayed, H. Hatakeyama, K. Kajimoto, Y. Yamada, K. Kataoka, H. Harashima, Lipid envelope-type nanoparticle incorporating a multifunctional peptide for systemic siRNA delivery to the pulmonary endothelium, *ACS Nano.* 7 (2013) 7534–7541. doi:10.1021/nm401317t.
- [34] R. Malaviya, J.D. Laskin, D.L. Laskin, Anti-TNF α therapy in inflammatory lung diseases, *Pharmacol. Ther.* 180 (2017) 90–98. doi:10.1016/j.pharmthera.2017.06.008.
- 505 [35] M.A. Deriu, N. Tsapis, M. Noiray, G. Grasso, N. El Brahmi, S. Mignani, J.-P. Majoral, E. Fattal, A. Danani, Elucidating the role of surface chemistry on cationic phosphorus dendrimer–siRNA complexation, *Nanoscale.* 10 (2018) 10952–10962.